Publicacións en colaboración con investigadores/as de Hospital Arnau de Vilanova (32)

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry

    Revista Portuguesa de Cardiologia, Vol. 42, Núm. 3, pp. 237-246

  3. Very long-term efficacy and safety of paclitaxel-eluting balloon after a bare-metal stent for the treatment of ST-elevation myocardial infarction: 8-year results of a randomized clinical trial (PEBSI study)

    Cardiovascular Diagnosis and Therapy, Vol. 13, Núm. 5

2022

  1. Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries

    Frontiers in Cardiovascular Medicine, Vol. 9

  2. Prognostic value of a model based on IC-BERG recommendations in ambulatory patients with heart failure

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 76-84

  3. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

    Journal of comparative effectiveness research, Vol. 11, Núm. 16, pp. 1173-1184

  4. Selection of the best of 2021 in clinical cardiology and COVID-19

    REC: CardioClinics, Vol. 57, pp. S17-S22

  5. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Comparison of One-Year Outcomes Between the ihtDEStiny BD Stent and the Durable-Polymer Everolimus- and Zotarolimus-Eluting Stents: A Propensity-Score-Matched Analysis

    Cardiovascular Revascularization Medicine, Vol. 31, pp. 1-6

  3. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC

    Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 438-448

2020

  1. Expert consensus statement on heart failure with reduced ejection fraction: beyond the guidelines

    Revista Espanola de Cardiologia Suplementos, Vol. 20, Núm. SB, pp. 1-46

  2. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

  3. Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial

    Drugs in Context, Vol. 9

  4. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706

  5. Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology

    Revista Espanola de Cardiologia, Vol. 73, Núm. 11, pp. 910-918

2019

  1. Lifestyle and cardiovascular risk factors in Spanish, Portuguese and Latin-American cardiologists. PREDICA survey

    REC: CardioClinics, Vol. 54, Núm. 1, pp. 17-26

  2. Role of rivaroxaban in the prevention of atherosclerotic events

    Expert Review of Clinical Pharmacology, Vol. 12, Núm. 8, pp. 771-780

  3. Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)

    Revista Espanola de Cardiologia, Vol. 72, Núm. 12, pp. 1020-1030

2017

  1. La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca

    Revista Espanola de Cardiologia, Vol. 70, Núm. 5, pp. 338-346